This assay was developed and validated to evaluate increased endostatin concentration as a potential new biomarker in mice with renal disease, and to compare endostatin with the established marker for nephropathy, blood urea nitrogen (BUN). This evidence concerns the gene COL18A1 and kidney disorder.